EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Chemotherapy improves survival for patients with lymph node-negative invasive papillary breast cancer with tumors ≥2 cm: a SEER population-based study

Yizi Zheng iD, Zhuozhao Zhan iD, Tingting Wu, Jiaqi Ying, Aina Zheng

The Oncologist · 2026

DOI: 10.1093/oncolo/oyaf422 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, 2026. Verfasst von Yizi Zheng und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, Zhejiang Key Laboratory of Intelligent Cancer Biomarker Discovery and Translation, The First Affiliated Hospital of Wen…. Hauptthemen laut MEDLINE: Breast Neoplasms, Carcinoma, Papillary. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Zhejiang Provincial Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Invasive papillary breast cancer (IPC) is a rare cancer known to have a better prognosis than other breast cancers. This study aimed to explore whether patients with early-stage IPC can benefit from chemotherapy. Materials and Methods IPC cases diagnosed between 2003 and 2021 were retrieved from the Surveillance, Epidemiology, and End Results (SEER) database. The Kaplan–Meier method and the Cox proportional hazard model were performed to identify significant prognostic factors. To eliminate selection bias and baseline characteristics, propensity score matching (PSM) was used. The primary endpoints were overall survival (OS) and breast cancer-specific survival (BCSS).

Results

A total of 1892 patients were enrolled, and 273 pairs were screened after PSM. Multivariable analysis showed that age under 50, married status, smaller tumor size, negative lymph node (LN) status, and receipt of surgery, chemotherapy or radiotherapy were independently associated with better OS. After PSM, patients receiving chemotherapy had significantly improved OS (P = .012), while BCSS showed no significant difference (P = .099). After stratified by tumor size and LN status, chemotherapy could significantly improve the OS of patients with LN-negative IPC with tumors ≥ 2.0 cm (P < .001). Among the patients with grade III or undifferentiated diseases, the OS of the chemotherapy group was significantly better than that of the non-chemotherapy group (P < .001).

Conclusions

For patients with LN-negative IPC with tumor ≥ 2.0 cm and patients with grade III or undifferentiated disease, chemotherapy significantly improved OS. Future randomized controlled trials are expected to validate the results.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsCarcinoma, PapillaryHumansFemaleSEER ProgramMiddle AgedAdultAgedPrognosisLymph NodesLymphatic Metastasis

Stichwörter der Autor:innen

breast cancerchemotherapyinvasive papillary carcinomaprognosis

Autor:innen und Institutionen

  • Department of Breast Surgery, Zhejiang Key Laboratory of Intelligent Cancer Biomarker Discovery and Translation, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, China.
  • Department of Thyroid and Breast Surgery, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Shenzhen University, Shenzhen, Guangdong 518035, China.
  • Department of Mathematics and Computer Science, Eindhoven University of Technology, Eindhoven, AZ 5612, The Netherlands.
  • The Operating Theater, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, China.

ORCID-Profile: Yizi Zheng, Zhuozhao Zhan

Förderung

  • National Natural Science Foundation of China
  • Zhejiang Provincial Natural Science Foundation of China

Zitieren

APA

Zheng, Y., Zhan, Z., Wu, T., Ying, J., & Zheng, A. (2026). Chemotherapy improves survival for patients with lymph node-negative invasive papillary breast cancer with tumors ≥2 cm: a SEER population-based study. The Oncologist. https://doi.org/10.1093/oncolo/oyaf422

Vancouver

Zheng Y, Zhan Z, Wu T, Ying J, Zheng A. Chemotherapy improves survival for patients with lymph node-negative invasive papillary breast cancer with tumors ≥2 cm: a SEER population-based study. The Oncologist. 2026. doi:10.1093/oncolo/oyaf422

BibTeX
@article{Zheng2026,
  author = {Zheng, Yizi and Zhan, Zhuozhao and Wu, Tingting and Ying, Jiaqi and Zheng, Aina},
  title = {Chemotherapy improves survival for patients with lymph node-negative invasive papillary breast cancer with tumors ≥2 cm: a SEER population-based study},
  journal = {The Oncologist},
  year = {2026},
  doi = {10.1093/oncolo/oyaf422}
}
Kostenlos starten →